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Superabsorbent wound dressings: 
A literature review
Highly exuding wounds can affect people of all ages with the inappropriate management of exudate leading to skin damage, pain, 
and reduced patient wellbeing (Wounds UK, 2013a). 
Effective exudate management can reduce time to 
healing, reduce dressing change frequency, and nurse 
input, thereby optimising healthcare efficiency. 
Superabsorbent dressings are designed to absorb 
and retain exudate. Products in this category include: 
Flivasorb® (Activa Healthcare; Flivasorb is known 
as Vliwasorb® [Lohmann and Rauscher] in Europe); 
Ecylpse® (Advancis Medical); KerraMax™ (Crawford); 
sorbion sachet extra (sorbion); Mextra® (Mölnlycke 
Health Care); and DryMax® Extra (Aspen). 
This article provides an overview of the literature 
relating to superabsorbent dressings discussing the 
evidence base for their use and offering criteria for 
dressing selection.
What are superabsorbent dressings?
The new generation of superabsorbent dressings 
contain polyacryate polymers (SAPs); these have 
hydroactive properties as a result of their high density 
ionic charge (Pytlik et al, 2005). They have the ability 
to swell to many times their original size and weight, 
holding large volumes of fluid while maintaining their 
structure (Dhodapkar et al, 2009). 
Superabsorbent polymers have been used 
since the 1980s and are commonly found in 
nappies, incontinence products, and feminine 
hygiene products. In recent years, there has been 
a considerable increase in the number of wound 
dressings that contain SAPs, (Cutting and Westgate, 
2012). However, the mere presence of SAPs does not 
guarantee optimal wound dressing performance; 
the fluid handling capacity of these dressings 
varies substantially, depending on the design and 
construction of the polymer, which may or may not be 
combined with other components to influence fluid 
handling (Cutting and Westgate, 2012).
SAPs are indicated for moderate to highly exuding 
wounds. They are designed to absorb and retain fluid, 
and so reduce the risk of leakage and maceration 
(Wiegand and White, 2013). Their substantial 
absorption capacity allows extended wear time, this 
reducing the frequency of dressing changes and the 
number of times the wound is disturbed, while still 
protecting the surrounding skin (Stephen-Haynes, 2011). 
Additionally, SAPs have been shown to have other 
properties that enhance wound healing. These include: 
Bioburden reduction in vitro (Wiegand et al, 2013).
Protease modulation in vitro, including reducing 
metalloproteinase (MMPs; specifically -2 and -9) 
and bacterial collagenase activity (Wiegand and 
White, 2013; Wiegand and Hipler, 2013).
Binding of elastase and antioxidant potential 
(Wiegand et al, 2011).
Literature revieW
To establish the evidence for the use of SAPs, a 
literature search was undertaken to generate a 
comprehensive list of publications relating to their use. 
Every attempt was made to ensure that the process of 
identifying studies was complete and unbiased. This 
article was not designed to be a systematic review, 
but rather to provide a summary of all published 
information in this area, with discussion and critical 
appraisal where appropriate.
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Superabsorbentdressingsarepromotedforuseonmoderatetohighlyexudatingwounds
toabsorbandretain fluid, thus reducing theriskof leakageandminimising therisk
ofmaceration.Thefluidhandlingcapacityofthesedressingsvariesdependingonthe
designandconstruction,notallshould,thereforeberegardedasequivalent.Thisarticle
providesanoverviewoftheliteraturerelatingtosuperabsorbentdressingsdiscussingthe
evidencebasefortheiruse.Twenty-ninearticleswereidentifiedasrelevanttothereview;
norelevantrandomisedcontrolledtrialswerelocated.Therewerenorestrictionsplaced
onliteraturesearchdates.TheonlyexclusioncriteriawasarticlesnotwritteninEnglish.
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The following electronic databases were 
searched: CInHAL, the Cochrane Central Register 
of Controlled Trials, the Cochrane Database of 
Systematic Reviews, the Database of Abstracts of 
Reviews of Effects, Health Technology Assessments 
and national Health Service Economic Evaluation, 
Embase, Ovid MEDLInE, PubMed, and Wounds 
UK. All databases were searched from their date of 
creation to 1 July 2013. Results were not restricted to 
recent years to ensure that all published studies were 
included. Reference lists from primary and review 
articles retrieved from the database searches were 
hand-screened to ensure no relevant articles were 
missed. Articles not written in English, and posters, 
were excluded.
The authors (RW, KO, LA) read all located articles 
and agreed all were to be included in the review. 
search terms 
Search terms used were: SAP$; superabsorbent 
polymers; supra absorbent polymers; superabsorbent$ 
dressings; superabsorbent$ dressings; super-
absorbent$ dressings; supra absorbent$ dressings; 
supra-absorbent$ dressings; hydration response 
technology (please note that the “$” symbol allows the 
search engine to retrieve content with all ending [i.e. 
wound, wounds, wounded, wounding, etc]).
revieW resuLts
In total, 29 articles were accepted for inclusion. none 
were randomised controlled trials.
Clinical performance
sorbion sachet extra
A convenience sample of 53 patients recruited over 
12 months from 12 hospital or community-based 
wound clinics was used for Cutting’s (2009) 5-week 
evaluation. All participants had either moderately 
or heavily exuding wounds. Wound types included: 
venous leg ulcers, pressure ulcers, diabetic foot 
ulcers, dehisced abdominal wounds, and vein graft 
donor site wounds. At baseline, 42 wounds were 
recorded as producing high, and 11 moderate, levels 
of exudate. The majority (n=36) of the wounds were 
over 12 weeks’ duration. Of the 42 wounds with high 
exudate levels at baseline, five had no exudate, six had 
light, nine had moderate, and 22 had high levels of 
exudate at week 4. Of the 11 wounds with moderate 
exudate levels at baseline, three were rated as having 
no exudate, two as light, five as moderate, and one 
high at week 4. The author reported that seven 
wounds increased in area by week 4, due to extensive 
comorbidities, general deterioration of the patient, 
patient death, and a reduction in dressing changes for 
unknown reasons (Cutting, 2009). 
In a health economics study using data acquired 
from the THIn database, Panca et al (2013) matched 
100 randomised venous leg ulcer patients treated with 
either AQUACEL® (ConvaTec), DryMax, Flivasorb, 
KerraMax, or sorbion sachet extra. The only clinical 
outcome of note was in the percentage change in 
wound area of unhealed wounds where AQUACEL-
treated wounds increased by 43%, while other 
unhealed wounds decreased by 20%–53% (P=0.001).
Flivasorb
Tadej (2009) described a single patient case study 
evaluating the use of Flivasorb in a patient with a 
highly exuding venous leg ulceration and concluded 
that Flivasorb enabled less frequent dressing change 
and reduced the risk of maceration leading to 
improvements in patient quality of life. 
Faucher et al (2012) conducted a multicentre, 
prospective, noncomparative observational study to 
evaluate the clinical efficacy and absorbency capacity 
of Flivasorb. Fifteen patients with copiously exuding 
wounds of any aetiology were recruited. These 
included inpatients and outpatients. The majority 
(n=8) had chronic wounds (53%), two had pressure 
ulcers (13%), and one (7%) had venous ulceration, 
three (20%) had ulcerating tumours. SAPs were used 
as a primary dressing in six cases (40%). The remaining 
patients had cavity wounds where a wound filler (e.g. 
an alginate) was required, with the SAP used as a 
secondary dressing. 
On presentation, 13 of the 15 patients reported 
problems with moderate to high exudate levels 
resulting in compromised surrounding skin condition; 
only two patients had healthy peri-wound skin. 
The surrounding skin condition was believed to be 
affecting the patients pain levels, with eight patients 
(53%) reporting moderate pain at dressings change. 
After 7 days use of a SAP, improvements in the 
condition of the surrounding skin were reported. 
Eleven patients (73%) were reported as having healthy 
peri-wound skin. In the remaining cases, maceration 
“All databases were 
searched from their 
date of creation to 
1 July 2013. Results 
were not restricted 
to recent years to 
ensure that all 
published studies 
were included.”
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of the surrounding skin improved, reducing from 
seven patients (46.7%) to only one (6.7%) in the same 
time period. In addition, they reported elimination 
of pain on dressing change due to improvements in 
surrounding skin. There was a reduction in dressing 
change frequency from daily to twice a week in 12 
(80%) cases following 3 days’ use of Flivasorb. The 
authors concluded that their results indicate effective 
fluid handling of exudate, reduction in peri-wound 
maceration and improvements in wound bed 
condition (Faucher et al, 2012).
nineteen patients with heavily exuding wounds 
who required dressing change three to seven times 
weekly consented to evaluate Flivasorb (Verrall 
et al, 2010). The sample consisted of a range of wound 
types: 16 established venous leg ulcers, one pressure 
ulcer, one arterial ulcer, and one chest wound. Results 
of the evaluation stated that nurses found Flivasorb 
did not adhere to the wound and reduced dressing 
changes by an average of one to two visits per week. 
The authors state that dressing changes were reduced 
in 100% of the cases, with the average dressing change 
being 3.2 compared to 1.8 when Flivasorb was used.
dryMax extra
Stephen-Haynes (2011) published a literature review 
of DryMax and three short case studies illustrating 
that DryMax retained and absorbed exudate. A 
further study (Stephen-Haynes and Stephens, 2012) 
in primary care involved 40 patients with wounds of 
various aetiologies and differing exudate types. 
Hindhede and Meuleneire (2012) presented a case 
series of 30 patients with acute and chronic wounds of 
various aetiologies, evaluating the capacity of DryMax 
Extra to manage excessive exudate. Eighteen of the 
patients had severely exuding wounds, nine had fairly 
large amounts of exudate, and three had moderately 
exuding wounds. Dressings were changed from a daily 
to once a week basis, based on the clinician’s judgment 
and the needs of the individual patient. 
The authors report that as the exudate levels 
decreased, so did pain levels. They reported one 
patient who required skin protection during the use 
of DryMax and one who reported pain due to the 
superabsorbent on removal. However, they state 
that when the dressing was moistened with a saline 
solution, the pain reduced. Their overall evaluation of 
the product was that it protected the wound borders 
from maceration, oedema, and erythema (Hindhede 
and Meuleneire, 2012).
Sixteen patients from four leg ulcer clinics were 
included in an evaluation of DryMax (Allymamod, 
2011): twelve patients had chronic venous leg ulcers, 
one a deep dermal burn on the lower limb that had 
failed to heal after 6 weeks, and one a category 3 
pressure ulcer on the heel. At the end of the first 
weeks’ evaluation, there was a marked improvement 
in both the wound bed and peri-wound skin with 
no reports of malodour. By the second week, 
patients required 15 fewer dressing changes, and 
by week four there were 44 fewer dressing changes. 
The author concluded that the use of DryMax had 
reduced clinic attendance, reduced costs in travel and 
inconvenience for the patients, thereby improving 
quality of life for this patient group. 
eclypse
Eclypse was clinically evaluated by Godar and Guy 
(2010) in four case studies. They identified patients 
suffering from highly exuding venous leg ulceration 
that resulted in more frequent dressing changes, 
due to strike through and subsequent problems 
with peri-wound skin. In all four cases they found 
clinical benefits using Eclypse dressings, reporting 
improvements with condition of surrounding skin, 
reduction in need for dressing changes, and reduction 
in wound size. 
Lloyd-Jones (2011) evaluated Eclypse as a primary 
and secondary dressing on a sample of ten patients. 
Results acknowledged the dressing managed exudate 
well, with dressing changes being reduced to 3–4 
days, rather than daily, and that the continence status 
of patients did not affect the wear time of sacral 
dressings. All patients reported that the dressings were 
comfortable, and also achieved a reduction in pain 
during dressing change and continuous pain. 
In two of the ten cases, Eclypse had been used as a 
secondary dressing, prior to Eclypse surgical pads had 
been used. Following the change of dressing regimen, 
dressing changes were reduced from 4 times daily to 
once every 2–3 days. Reported pain scores decreased 
from 10 to 9 immediately, with a further reduction to 
5 after 1 week. 
Eclypse is also available in “boot” form, where it has 
been used successfully in the management of cellulitis 
(Rafter, 2011).
“Lloyd-Jones (2011) 
evaluated Eclypse® 
(Advancis Medical) 
as a primary and 
secondary dressing 
on a sample of ten 
patients. Results 
acknowledged the 
dressing managed 
exudate well, with 
dressing changes 
being reduced to 
3–4 days, rather 
than daily.”
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KerraMax 
Hampton et al (2011) published a single patient case 
study using honey dressings in combination with 
KerraMax. They describe a 102-year-old patient 
with a long history of venous ulceration complicated 
by arterial disease (ankle–brachial pressure index, 
0.7). The ulcer was highly exuding with evidence of 
colonisation by a Pseudomonas spp., but the authors 
do not report if the wound was infected or the 
levels of Pseudomonas. After 1 month of treatment, 
a reduction in wound pain and exudate level, 
improvement in condition of the wound bed and of 
surrounding skin, and also general improvements in 
the patient’s quality of life were reported.
Mextra
This is the most recent product to become available 
on the UK market. So far, the only available published 
evidence is that of MMP binding in vitro (Wiegand 
and Hipler, 2013). 
alteration to sub-bandage pressures 
As might be anticipated, the swelling of an absorbent 
dressing in a confined space (i.e. between compression 
bandage and wound) is likely to increase local 
pressure. Accordingly, an evaluation of four SAPs 
(Flivasorb, sorbion sachet extra, KerraMax, Eclypse) 
was undertaken by Cook (2011) to investigate if 
these dressings altered sub-bandage pressures when 
polymers in the dressing expanded. 
Results showed that sub-bandage pressures altered 
following expansion of the superabsorbent dressing 
under compression therapy, with Eclypse having the 
smallest effect (a 2.5% pressure increase), and Flivasorb 
increasing sub-bandage pressure by 38% when 
used under 4-layer compression bandaging. Similar 
increases were seen when using 2-layer compression 
systems, ranging from a 0% increase with Eclypse to 
24% with Flivasorb. It is worth noting that this was a 
small evaluation and lacked depth, rigour, and validity. 
However, it does identify that an alteration of sub-
bandage pressure in this range of products deserves 
consideration as it may lead to detrimental effects on 
ulcer healing, patient comfort, and compliance with 
compression therapy (Cook, 2011).
evidence for antimicrobial activity
The capacity of any wound dressing to reduce 
bioburden will depend on a number of factors related 
to composition and mode of action. Dressings may 
be impregnated with antimicrobial compounds, or 
have the capacity to sequester microorganisms (i.e. 
to adsorb them onto the surface, such that they are 
removed when dressings are changed). 
When considering any in vivo action of SAPs, it is 
important to consider all possible modes of action. 
Where an antimicrobial compound is included in 
the formulation (e.g. polyhexamethylene biguanide 
[PHMB] has been used in one SAP), the antimicrobial 
effect will depend on the concentration and 
bioavailability of that agent. 
For non-medicated SAPs, it has been claimed 
that the capacity of a dressing to absorb and retain 
(i.e. sequester) bacteria is an important function, 
particularly in chronic wounds (Wysocki, 2002). In 
vitro and animal in vivo microbiological studies have 
illustrated the extent of this effect in superabsorbent 
dressings (Eming et al, 2008).
Wiegand et al (2011) using Vliwasorb, have 
demonstrated this quantitative antibacterial effect. 
The authors compared two SAPs according to an 
international standard method (Japanese Industrial 
Standard, 2002; Monticello and Askew, 2013). Both 
SAPs were found to reduce numbers of Pseudomonas 
aeruginosa, Klebsiella pneumoniae, and Escherichia 
coli by over 3 log units, while growth of Staphylococcus 
aureus and Candida albicans was reduced by 2 log 
units. While this fails to show a difference between 
these two SAPs in vitro, it does not imply that all SAPs 
are of equal effect in this respect.
This bacterial sequestration mechanism would have 
the distinct advantage of not selecting for resistance 
as the function is purely physical. To what degree this 
applies to the many other SAPs on the market remains 
to be demonstrated, as does any in vivo or clinical 
significance.
Criteria For seLeCting a sap
For optimal clinical and cost-effectiveness, the 
following selection criteria, based on the published 
literature and manufacturers’ instructions for use, 
may prove helpful:
Wound exudate level: Do not use on dry or lightly 
exuding wounds.
Wound bed preparation: Application of the 
TIME framework (Leaper et al, 2012) to SAP 
“An evaluation 
of four super-
absorbent dressings 
… showed that sub-
bandage pressures 
altered following 
expansion of the 
dressing under 
compression 
therapy, with 
Eclypse having 
the smallest effect 
(a 2.5% pressure 
increase).”
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clinical use indicates good moisture (M) control. 
Influence on inflammation (I) via MMP binding is 
established for some SAPs, but not all. The impact 
on infection via sequestration of bioburden is 
established in vitro, but the clinical implications 
are yet to be demonstrated. There is, as yet, no 
compelling evidence on tissue (T) by debridement, 
or promotion of granulation.
Delayed healing: Those SAPs with proven MMP-
binding and bacterial sequestration properties may 
have an impact.
Select size, shape, and adhesive/nonadhesive: 
The available SAPs vary in this respect, select the 
most appropriate. nonadhesive products will 
require fixation retention and so incur additional 
costs. One SAP product, the Eclypse boot, is 
available as a lower-leg enclosure, indicated for 
“leaky legs” as may occur with leg and foot ulcers 
and lympheodema (Rafter, 2011).
Wear time: Extended wear time is not everything; 
dressings laden with exudate become heavy, 
dressing swelling leads to increased pressure, and 
the antimicrobial activity is likely to diminish with 
saturated dressings (Wiegand et al, 2013). Patients 
find heavy dressings uncomfortable and may wish 
to have hygiene performed more frequently to 
maintain quality of life.
Wound infection: The bioburden reduction 
function of some SAPs has yet to be related to any 
clinical impact on critical colonisation or infection.
Compression: Be aware of those dressings that 
swell and increase local pressure.
Patient preference: Always consider the comfort 
and concordance of the patient when making 
dressing choices.
Ease of application and removal: Dressing 
flexibility and conformability can be problematic on 
application.
Overall cost-effectiveness: Unit dressing cost has 
been linked to fluid uptake (Cutting and Westgate, 
2012). However, this is not formal cost-effectiveness. 
not all dressings will be left in situ until they are 
saturated, so this calculation is not definitive. 
SAPs have been evaluated for clinical and cost-
effectiveness in the treatment of venous leg ulcers by 
Panca et al (2013), who found sorbion sachet extra 
to be cost-effective when compared with KerraMax, 
Flivasorb, and DryMax Extra. Wuk
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